pharma · Glaucoma · Macular Edema
Allergan Pharmaceuticals International Limited
Allergan Pharmaceuticals International drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Allergan Pharmaceuticals International drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Sensory organs (S01) compound in Allergan Pharmaceuticals International's portfolio. Molecular target: Vascular endothelial growth factor A, long form.
US regulatory status: approved. Molecular target: Synaptosomal-associated protein 25.
US regulatory status: approved. Molecular target: Prostaglandin F2-alpha receptor.
Musculo-skeletal system (M03) compound in Allergan Pharmaceuticals International's portfolio. Molecular target: Synaptosomal-associated protein 25.
Dermatologicals (D11) compound in Allergan Pharmaceuticals International's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
US regulatory status: approved. Molecular target: DNA gyrase.
US regulatory status: approved. Molecular target: Cyclooxygenase.